Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Expert Opin Investig Drugs ; 30(5): 505-518, 2021 May.
Artigo em Inglês | MEDLINE | ID: mdl-33721548

RESUMO

Background: COVID-19 has several overlapping phases. Treatments to date have focused on the late stage of disease in hospital. Yet, the pandemic is by propagated by the viral phase in out-patients. The current public health strategy relies solely on vaccines to prevent disease.Methods: We searched the major national registries, pubmed.org, and the preprint servers for all ongoing, completed and published trial results.Results: As of 2/15/2021, we found 111 publications reporting findings on 14 classes of agents, and 9 vaccines. There were 62 randomized controlled studies, the rest retrospective observational analyses. Only 21 publications dealt with outpatient care. Remdesivir and high titer convalescent plasma have emergency use authorization for hospitalized patients in the U.S.A. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome. Monoclonal antibodies are authorized for outpatients, but supply is inadequate to treat all at time of diagnosis. Favipiravir, ivermectin, and interferons are approved in certain countries.Expert Opinion: Vaccines and antibodies are highly antigen specific, and new SARS-Cov-2 variants are appearing. We call on public health authorities to authorize treatments with known low-risk and possible benefit for outpatients in parallel with universal vaccination.


Assuntos
Vacinas contra COVID-19/administração & dosagem , COVID-19/terapia , Assistência Ambulatorial/métodos , Anticorpos Monoclonais/administração & dosagem , COVID-19/diagnóstico , COVID-19/prevenção & controle , Hospitalização , Humanos , Imunização Passiva , Ensaios Clínicos Controlados Aleatórios como Assunto , Fatores de Tempo , Tratamento Farmacológico da COVID-19 , Soroterapia para COVID-19
2.
AIDS Rev ; 23(1): 40-47, 2021 02 08.
Artigo em Inglês | MEDLINE | ID: mdl-33556957

RESUMO

COVID-19, caused by SARS-CoV-2, continues to be a major health problem since its first description in Wuhan, China, in December 2019. Multiple drugs have been tried to date in the treatment of COVID-19. Critical to treatment of COVID-19 and advancing therapeutics is an appreciation of the multiple stages of this disease and the importance of timing for investigation and use of various agents. We considered articles related to COVID-19 indexed on PubMed published January 1, 2020-November 15, 2020, and considered papers on the medRxiv preprint server. We identified relevant stages of COVID-19 including three periods: pre-exposure, incubation, and detectable viral replication; and five phases: the viral symptom phase, the early inflammatory phase, the secondary infection phase, the multisystem inflammatory phase, and the tail phase. This common terminology should serve as a framework to guide when COVID-19 therapeutics being studied or currently in use is likely to provide benefit rather than harm.


Assuntos
Tratamento Farmacológico da COVID-19 , Ensaios Clínicos como Assunto , SARS-CoV-2 , COVID-19/complicações , COVID-19/imunologia , Síndrome da Liberação de Citocina/etiologia , Humanos , RNA Viral/análise , Fatores de Tempo , Replicação Viral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA